אודות פרק זה
The deadliest nicotine products in America remain the easiest to buy, while lower-risk alternatives face the toughest fight for regulatory approval and political acceptance. It’s a striking contrast.
Despite recent progress at the FDA, nicotine pouches remain caught in vaping’s regulatory and political wake. They are inheriting the regulatory paralysis, legislative backlash, and moral panic created by the battle over vaping.
In Part 1 of this three-part RegWatch special series, Laura Leigh Oyler, Vice President of Regulatory Affairs for Haypp Group, draws on 17 years in tobacco harm reduction to explain the stakes for adult consumers, responsible retailers, and public health.
Oyler breaks down the FDA’s years-long PMTA delays, its failure to provide pouch-specific guidance, the growth of illicit and counterfeit products, and the landmark modified-risk authorization permitting the claim that using ZYN instead of cigarettes reduces the risk of serious disease. She also warns that tobacco control is already branding nicotine pouches as “the next Juul,” driving fear and misinformation into state legislation.
With more than 1,200 combustible tobacco products authorized since 2020 and millions of Americans still smoking, why do the lowest-risk alternatives continue to face the greatest resistance?
Find out. Only on RegWatch by RegulatorWatch.com.
Only on RegWatch by RegulatorWatch.com.
Released: July 25, 2026
Produced by: Brent Stafford
CELEBRATE WITH US | RegWatch 10th Anniversary Fundraising Campaign
GoFundMe: https://www.gofundme.com/f/regwatch-10th-anniversary-fundraiser
#RegWatch #VapeNews
